about
Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survivalAnti-prion activity of an RNA aptamer and its structural basisThermodynamic Stabilization of the Folded Domain of Prion Protein Inhibits Prion Infection in VivoAnti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approachesThe distribution of four trace elements (Fe, Mn, Cu, Zn) in forage and the relation to scrapie in IcelandMisfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALSEffects of Various Flavonoids on the α-Synuclein Fibrillation Process.Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivoA porphyrin increases survival time of mice after intracerebral prion infectionInfluence of Mabs on PrP(Sc) formation using in vitro and cell-free systemsInhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides.Comparative Study of Prions in Iatrogenic and Sporadic Creutzfeldt-Jakob Disease.Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.The intricate mechanisms of neurodegeneration in prion diseases.The cellular prion protein (PrP(C)): its physiological function and role in diseaseDiscovery of Novel Anti-prion Compounds Using In Silico and In Vitro ApproachesAntiprion activity of cholesterol esterification modulators: a comparative study using ex vivo sheep fibroblasts and lymphocytes and mouse neuroblastoma cell lines.The physics of the interactions governing folding and association of proteins.Inhibition of PrP(Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives.Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria.Current and future molecular diagnostics for prion diseases.Antiprion prophylaxis by gene transfer of a soluble prion antagonist.An update on pharmacological approaches to neurodegenerative diseases.Detection and control of prion diseases in food animals.Pharmacological chaperone reshapes the energy landscape for folding and aggregation of the prion proteinImmunotherapy for prion diseases: opportunities and obstacles.Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose.Prion protein self-interaction in prion disease therapy approaches.Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit.In silico strategies on prion pathogenic conversion and inhibition from PrPC -PrPSc.Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.Prophylactic effect of dietary seaweed Fucoidan against enteral prion infection.Copper-dependent co-internalization of the prion protein and glypican-1.Temporal Resolution of Misfolded Prion Protein Transport, Accumulation, Glial Activation, and Neuronal Death in the Retinas of Mice Inoculated with Scrapie.Toxicological Evaluation of Anti-Scrapie Trimethoxychalcones and Oxadiazoles.Synthesis of an (11) C-labeled antiprion GN8 derivative and evaluation of its brain uptake by positron emission tomography.Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation.A promising anti-prion trimethoxychalcone binds to the globular domain of PrP(C) and changes its cellular location.FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice.
P2860
Q27313215-27911563-5F18-46DE-9061-C98B7AFA6E43Q27675235-4FED1CA5-FEE8-4DE9-959D-4609DEC133A9Q27679150-6EF8D7FA-E8B5-420F-9B8D-A4D33C0F6CE9Q28538336-CF338474-316B-41EA-ABED-CE8B12E1C8C1Q33934161-B528698E-12EC-48F6-9F42-B1127B0A9357Q34139970-B54755C4-407A-4C98-835B-8EE5A20628D7Q34211735-A023DC64-7607-42CF-882A-C2992D3E5836Q34301832-1800DE24-6753-4628-AFF5-52A9C9458075Q34352240-1503C23C-F24F-4C6C-8B25-333D17906396Q34358708-C74AB4B3-62C0-4EC8-B5A0-E3F442F0DE88Q34378331-BACC8EA1-3A8E-43C1-B4F5-36FAAEE3239BQ34509751-875F2ADD-3CC9-485D-9073-509AA33B2438Q34556132-A36EB79F-7AA9-4A28-B73B-05CA7F32B2AEQ34633462-CDC3CF9E-192D-41F8-98A8-E628A2910D48Q34664576-A81D0DEE-7E43-4056-A599-97D0C92760CFQ36003019-67DE07C7-06DE-4057-9218-167444158914Q36139197-A432853E-8504-4B2E-9571-FE889810AE05Q36295466-CBC7B0CE-A0C1-420E-8EEC-14E7BFB38D49Q36420053-74D602E9-A4C9-4F11-94A7-E69C794A50EEQ36436176-E57047E1-A14C-48D1-8F43-FE6D325A2109Q36499141-B39CF5A2-1F64-41AD-835C-6D53C730B807Q36528891-725C041D-1D3E-4702-A03E-D0752A16BC21Q36579822-F4E8C686-10A6-4699-895E-D3E8822128C8Q36677402-56A3EAF1-DF03-453C-B1A7-10E153F29F69Q36857700-DADB399B-431F-4F8F-A801-DE080C835030Q37060996-4235FF75-5DA0-4725-8014-980372736E7FQ37773260-F16B54F7-8BD1-4DB3-8458-8ACD6A5FCC88Q37807985-DECD0023-680E-48BF-8445-26736687FB3AQ37949697-B43CC1C7-1849-4D3F-BEF5-8C413DDA3A7EQ37951515-601B8DBC-BBE5-445C-9D39-325EEFFBBAB5Q39101358-223DF3E6-2EBE-4C95-BD38-563109B5FA89Q40078261-371A4A54-11A5-4385-BC93-EC8336885A67Q40145106-D076C520-CEDA-4523-9483-E7D73D169C23Q40241315-A4A82328-7B0E-47FD-8144-8B70D2AE421EQ40623674-973B7402-11B7-4172-922B-11D3C6215C24Q41069574-5302208B-BEE9-4B9C-89E6-1D83E3D6758EQ42261396-5EF04257-87CD-4DD3-AA46-7E6E7EE13E70Q46905202-39BED6D3-5A43-4A43-A0A3-3A081A4CBF15Q47406923-28FA7FE3-9475-49D5-B3A8-226361DC0C1AQ50878634-F76DBAB9-7882-4296-A80D-A68F0D5DE509
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Prion diseases--close to effective therapy?
@ast
Prion diseases--close to effective therapy?
@en
type
label
Prion diseases--close to effective therapy?
@ast
Prion diseases--close to effective therapy?
@en
prefLabel
Prion diseases--close to effective therapy?
@ast
Prion diseases--close to effective therapy?
@en
P2860
P356
P1476
Prion diseases--close to effective therapy?
@en
P2093
Neil R Cashman
P2860
P2888
P304
P356
10.1038/NRD1525
P577
2004-10-01T00:00:00Z